Patrick Heron Biography and Net Worth

Director of Mirum Pharmaceuticals

Patrick Heron has served as a member of our board of directors since November 2018. Mr. Heron is a general partner with Frazier, a position he has held since September 1999. Mr. Heron has been active in company formations and initial investments in various biotechnology companies, including Marcadia Biotech Inc., Calixa Therapeutics, Inc., and VentiRx Pharmaceuticals, Inc., He also led Frazier’s involvement in MedPointe Inc. Prior to joining Frazier, Mr. Heron helped develop McKinsey & Co.’s West Coast biotechnology consulting practice. Mr. Heron currently serves on the board of directors of Iterum Therapeutics pic, a public pharmaceutical company, as well as private companies Amunix Therapeutics, Inc., Imago Biosciences, Inc., Silvergate Pharmaceuticals, Inc., Arcutix, Inc., SutroVax, Inc., PassageBio, Inc., and Recida Therapeutics, Inc. He previously served on the boards of directors of the public biopharmaceutical companies Tobira and Collegium Pharmaceuticals, Inc. Mr. Heron received a B.A. in political science from the University of North Carolina at Chapel Hill and an M.B.A. from Harvard Business School.

What is Patrick J. Heron's net worth?: The estimated net worth of Patrick J. Heron is at least $7.57 million as of March 4th, 2025. Mr. Heron owns 163,643 shares of Mirum Pharmaceuticals stock worth more than $7,573,398 as of March 27th. This net worth estimate does not reflect any other investments that Mr. Heron may own. Learn More about Patrick J. Heron's net worth.
How do I contact Patrick J. Heron?: The corporate mailing address for Mr. Heron and other Mirum Pharmaceuticals executives is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. Mirum Pharmaceuticals can also be reached via phone at (650) 667-4085 and via email at ir@mirumpharma.com. Learn More on Patrick J. Heron's contact information.
Has Patrick J. Heron been buying or selling shares of Mirum Pharmaceuticals?: During the last quarter, Patrick J. Heron has bought $60,835.95 of Mirum Pharmaceuticals stock. Most recently, on Tuesday, March 4th, Patrick J. Heron bought 1,335 shares of Mirum Pharmaceuticals stock. The stock was acquired at an average cost of $45.57 per share, with a total value of $60,835.95. Following the completion of the transaction, the director now directly owns 163,643 shares of the company's stock, valued at $7,457,211.51. Learn More on Patrick J. Heron's trading history.
Who are Mirum Pharmaceuticals' active insiders?: Mirum Pharmaceuticals' insider roster includes Eric Bjerkholt (CFO), Ian Clements (CFO), James Flynn (Major Shareholder), Michael Grey (Chairman of the Board), Patrick Heron (Director), Jolanda Howe (SVP), Lara Longpre (Chief Development Officer), Christopher Peetz (Co-Founder, CEO and Director), Joanne Quan (Chief Medical Officer), Peter Radovich (President & Chief Operating Officer), Saira Ramasastry (Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Mirum Pharmaceuticals?: During the last twelve months, Mirum Pharmaceuticals insiders bought shares 4 times. They purchased a total of 3,680 shares worth more than $124,300.35. During the last twelve months, insiders at the sold shares 17 times. They sold a total of 172,113 shares worth more than $7,304,987.14. The most recent insider tranaction occured on March, 17th when SVP Jolanda Howe sold 57,606 shares worth more than $2,554,826.10. Insiders at Mirum Pharmaceuticals own 22.9% of the company. Learn More about insider trades at Mirum Pharmaceuticals.
Information on this page was last updated on 3/17/2025.

Patrick J. Heron Insider Trading History at Mirum Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2025	Buy	1,335	$45.57	$60,835.95	163,643
9/18/2024	Buy	115	$37.40	$4,301.00	162,308
9/6/2024	Buy	230	$41.58	$9,563.40	162,193
9/11/2023	Buy	4,687	$30.30	$142,016.10	152,678
8/31/2023	Buy	147,991	$26.25	$3,884,763.75	147,991
7/22/2019	Buy	450,000	$15.00	$6,750,000.00

Patrick J. Heron Buying and Selling Activity at Mirum Pharmaceuticals

Mirum Pharmaceuticals Company Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Today's Range

Now: $46.28

$45.83

$47.20

50 Day Range

MA: $48.02

$43.01

$53.16

2 Week Range

Now: $46.28

$23.14

$54.23

Volume

393,047 shs

Average Volume

509,454 shs

Market Capitalization

$2.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04